Here's a roundup of the key takeaways from Wall Street analysts this week.
Here's a roundup of the key takeaways from Wall Street analysts this week.
Sarepta
What happened? On Monday, BMO upgraded Sarepta Therapeutics Inc (NASDAQ:SRPT) to Outperform with a $50 price target.
*Quick Take: Elevidys rollout is surprising; SRPT risks are skewed. Buy the fear, upside is inevitable.
Full Story: BMO upgrades SRPT to Outperform with a $50 price target. Yes, an outpatient fatality could destroy Elevidys' viability—and send SRPT shares crashing to $12-$15—but here's the thing: the market is already pricing that out. BMO's physician survey and FAERS data show Elevidys' rollout is accelerating, with sales poised to surprise in Q3 and Q4 2025. Meanwhile, DM1/FHSD results by the end of 2025 could open up new revenue streams, attracting fresh investment.
Of course, the $50 price optimism scenario depends on the absence of tragedy (the probability
Keep it simple. Buy on fear.
CoreWeave
What happened? On Tuesday, Wells Fargo upgraded CoreWeave Inc (NASDAQ:CRWV) to Overweight with a $170 price target.
*Quick Take: CRWV dominates AI infrastructure. Already printing money.
Full Story: Wells Fargo upgrades CRWV to Overweight with a $170 price target, betting on its dominance in AI infrastructure while the broader software landscape remains dormant. The hyperscaler shortage through 2026 is CRWV's playground, and the clean check from NVDA—an agreement to purchase unused capacity through 2032—is the icing on the cake. WFC sees CRWV gaining market share as MSFT, GOOGL (likely an unnamed client with $0.5 billion in receivables) and others are expanding their partnerships. Latent demand and NVDA's safety net make it an obvious choice.
WFC is also improving CRWV's economics. GPU monetization assumptions now reach $2.50/hour (up from $2), matching OpenAI's 110,000 GPU contract rate, and funding rates are falling to 9% from 10%. The result? Variable margins soar to 28% per GPU from 7%. Wells Fargo is raising its revenue forecasts for fiscal years 2026/2027 by 5%/9%. CRWV isn't just winning the AI creation cycle—it's printing money.
General Motors
What happened? On Wednesday, UBS upgraded General Motors Company (NY:GM) to Buy with a target price of $81.
*Quick Summary: UBS upgrades GM to Buy. Expects higher earnings per share and margins.
Full Story: UBS upgrades GM to Buy, with 2026/27 EPS estimates 35%/42% above consensus. The bank sees GMNA margins reaching their target of 8-10%, while the market is stuck at 6-6.5%. While tariffs increase costs that GM will not pass on to consumers, UBS believes the automaker has aces up its sleeve to offset the negative factors. The bank views GM as a potential beneficiary of lower US rates and capital expenditure cycles, with a strong free cash flow profile and a capital allocation policy supporting annual share repurchases at high single-digit levels. With an FCF yield of approximately 14% in 2025, UBS sees positive momentum, with the market pricing 2026 EPS at 27% below UBS estimates.
Positive catalysts include the EPA's final emissions decision and official guidance for 2026.
Frontier Airlines
What happened? On Thursday, Seaport Global assigned Frontier Airlines a "Neutral" rating without specifying a target price.
*Shortcut: Frontier's outlook is dependent on its peers. The neutral rating reflects uncertainty.
Full story: Seaport begins coverage of Frontier Group with a neutral rating, acknowledging option-like volatility in the stock. The firm sees upside to $12-$15 if Spirit liquidates—an unlikely but plausible scenario—and downside risk if Spirit's exit from Chapter 11 puts pressure on Frontier through $100 million in pilot payroll savings. Meanwhile, Frontier's "New Frontier" strategy—premium products, digital tools, loyalty programs—could drive shares to $7 based on 2026 earnings of $0.60 per share. But here's the catch: growth in higher-fare VFR markets and a favorable competitive environment may not be enough to offset excess capacity in key markets. After all, profit is what competitors can afford.
Ciena
What happened? On Friday, Rosenblatt upgraded Ciena Corp (NY:CIEN) to Buy with a $175 price target.
*Brief Takeaway: Ciena benefits from AI clusters. Growth trajectory looks optimistic.
Full Story: Rosenblatt upgrades CIEN to Buy, riding the wave of the Scale Across AI data center cluster interconnection craze. Ciena has already secured a lucrative deal with a hyperscaler, connecting two 100,000-GPU giants over 100 km using WaveLogic 6 Nano 800G ZR pluggable modules. This customer deploys 20 petabytes of capacity, pushing Ciena to develop multi-rail amplifiers that reduce space (-98%) and power consumption (-30%) when illuminating hundreds of fiber pairs. The analyst values this deal at approximately $200 million, but rumors of more deals are swirling as Ciena targets the data center interconnection prize using pluggable modules or integrated DWDM, depending on the required distance and performance.
New target price? A cool $175, up from $127.50, based on a 40x consensus FY26 EPS and a 25x FY27 earnings estimate of $7 per share. Rosenblatt expects the rest of the herd to release their FY27 estimates next quarter. But that's not all: Ciena is targeting data center penetration and components, having already inked a nine-figure deal with Meta (designated an extremist organization and banned in Russia) for out-of-band management using PON. And with the acquisition of Nubis, it's opening up the opportunity to sell electrical retimer chips. Long-term, the real action is in CPO modules and the penetration of coherent lightweight modulation into campuses and data center cores. Buckle up, this ride is just getting started.